Patients & Visitors ›

Profile

Profile
Research

Robert J. Applegate, M.D.

Professor, Cardiology

Clinical Specialties

Angioplasty, Cardiac Catheterization, Cardiology (clinical), Cardiology (interventional)

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-716-6674
Department: 336-716-7631

Media Medical Expert »

Insurance Accepted »

Education & Training

B.A., University of California-Los Angeles , 1973
M.D., University of Virginia School of Medicine , 1980
B.S., San Jose State University , 1976
Internship, Medicine, Oregon Health Science Univ School of Medicine, 1981
Residency, Medicine, Oregon Health Science Univ School of Medicine, 1983
Fellowship, University of Texas Health Sci Center-San Antonio, 1984
Fellowship, University of Texas Health Sci Center-San Antonio, 1986

Board Certifications

American Board of Internal Medicine, Cardiovascular Disease
American Board of Internal Medicine, Interventional Cardiology
American Board of Internal Medicine, Internal Medicine

Memberships

American College of Cardiology
Am Federation Of Clinical Rese
Aha - Council On Cardiology
Forsyth-Davie-Stokes Medical S

NPI Number

1740265032

Robert J. Applegate, M.D.

Professor, Cardiology

Research Interests

cardiac function, drugs/therapeutic agents pharm, health services, research/outc, vascular diseases

Contact Information

Academic: 336-716-2718 | Department: 336-716-7631

Media Medical Expert »

Recent Publications

Anderson J, Sacrinty M, Turner S, Gandhi S, Santos R, Kutcher M, Little W, Applegate R. Gender differences in vascular complications associated with transfemoral and transradial cardiac catheterization and PCI: a single-center experience [abstract]. J Am Coll Cardiol. 2013;61(10 Suppl):E77.

Applegate RJ, Sacrinty M, Gandhi S, Kutcher M, Santos R, Little W. Cost effectiveness of Everolimus-eluting compared to propensity score matched bare metal stenting: an analysis of a selected stent strategy [abstract]. J Am Coll Cardiol. 2013;61(10 Suppl):E1505.

Butler M, Sacrinty M, Little W, Applegate R, Kutcher M, Santos R, Gandhi S. Peak troponin I greater than 5 times the 99th percentile after PCI does not define a high-risk group [abstract]. J Am Coll Cardiol. 2013;61(10 Suppl):E1879.

Freilich MI, Gossman DE, Applegate RJ, Werns SW, Gips SJ, Turi ZG. The 'bladder sign'--an important early marker of retroperitoneal hemorrhage. Catheter Cardiovasc Interv. 2012;79(1):158-165.

Noureddine ND, Applegate RJ. Drug-eluting stents versus bare metal stents in ST elevation myocardial infarction: from evidence to practice. Minerva Cardioangiol. 2012;60(1):1-9.

Schafer P, Sacrinty MT, Smith JW, Little W, Gandhi S, Kutcher M, Santos R, Smith T, Cecile AC, Applegate R. Cost-effectiveness analysis of propensity matched radial and femoral cardiac catheterization and coronary intervention [abstract]. J Am Coll Cardiol. 2012;59(13 Suppl):E72.

Hermiller JB, Sudhir K, Applegate RJ, Rizvi A, Wang J, Gordon PC, Yaqub M, Cao S, Ferguson JM, Smith RS Jr, Sood P, Stone GW. Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. EuroIntervention. 2012;8(1):87-93.

Applegate RJ. Vascular closure device failure: we are getting better but not there yet [editorial comment]. JACC Cardiovasc Interv. 2012;5(8):845-847.

Lansky AJ, Brar SS, Yaqub M, Sood P, Applegate RJ, Lazar D, Jankovic I, Hermiller JB, Koo K, Sudhir K, Stone GW. Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three years. Am J Cardiol. 2012;110(1):21-29.

Turner S, Sacrinty M, Manogue M, Little W, Gandhi S, Kutcher M, Santos R, Applegate R. Transitioning to the radial artery as the preferred access site for cardiac catheterization: an academic medical center experience. Catheter Cardiovasc Interv. 2012;80(2):247-257.

Jollis JG, Al-Khalidi HR, Monk L, Roettig ML, Garvey JL, Aluko AO, Wilson BH, Applegate RJ, Mears G, Corbett CC, Granger CB. Expansion of a regional ST-segment-elevation myocardial infarction system to an entire state. Circulation. 2012;126(2):189-195.

Butler MM, Applegate RJ. Complex PCI in an elderly diabetic patient with advanced chronic kidney disease [clinical case update]. Contrast-Induced Nephropathy Education. 2012;August():1-6.

Waksman R, Torguson R, Kaneshige K, Kirtane A, Ryan T, Raber L, Applegate R, Waxman S, Cohen D, Gordon P. Angiographic correlates of late and very late drug-eluting stent thrombosis: findings from the international multicenter Drug Eluting Stent Event Registry of Thrombosis (DESERT) [abstract]. Eur Heart J. 2012;33(Suppl 1):389.

Applegate R, Sacrinty M, Allem J, Gandhi S, Kutcher M, Santos R, Smith T, Little W. Contrast use and acute kidney injury in contemporary clinical practice [abstract]. J Am Coll Cardiol. 2012;60(17 Suppl B):B39-B40.

Applegate R, Sacrinty M, Gandhi S, Kutcher M, Santos R, Smith T, Little W. Cost effectiveness of Everolimus-eluting stents compared to first generation drug-eluting stents in contemporary clinical practice [abstract]. J Am Coll Cardiol. 2012;60(17 Suppl B):B185.

Ohara T, Anzai T, Yasuda S, Ogawa H, Applegate R, Little W. Diastolic function at rest determines the prognosis of myocardial infarction [abstract]. J Card Fail. 2012;18(10 Suppl 1):S190.

Waksman R, Torguson R, Kaneshige K, Kirtane A, Ryan T, Raber L, Applegate R, Waxman S, Cohen D, Gordon P. Drug-eluting stent event registry of thrombosis (DESERT): the International Drug-Eluting Stent Thrombosis Registry, angiographic assessment [abstract]. J Am Coll Cardiol. 2012;60(17 Suppl):B180-B181.

Pervaiz MH, Sood P, Sudhir K, Hermiller JB, Hou L, Hattori K, Su X, Cao S, Wang J, Applegate RJ, Kereiakes DJ, Yaqub M, Stone GW, Cutlip DE. Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. Circ Cardiovasc Interv. 2012;5(2):150-156.

Humphrey HL, Applegate RJ. Risk scoring systems for PCI: does one size fit all? [commentary]. J Invasive Cardiol. 2011;23(2):70-71.

Applegate RJ, Yaqub M, Hermiller JB, Sood P, Yu S, Doostzadeh J, Williams JE, Farhat N, Caputo R, Lansky AJ, et al. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). Am J Cardiol. 2011;107(6):833-840.

Applegate RJ. Toward better stratification of patients with left main disease value of clinical and angiographic-derived risk scores [editorial comment]. JACC Cardiovasc Interv. 2011;4(3):298-299.

Applegate RJ. Optimal therapy for ST-segment elevation myocardial infarction: the role of residual thrombus [editorial comment]. J Am Coll Cardiol. 2011;57(19):1874-1876.

Ng VG, Lansky AJ, Hermiller JB, Farhat N, Applegate RJ, Yaqub M, Sood P, Su X, Simonton CA, Sudhir K, et al. Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial). Am J Cardiol. 2011;107(6):841-848.

Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents: 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol. 2011;58(1):19-25.

Dauerman HL, Rao SV, Resnic FS, Applegate RJ. Bleeding avoidance strategies: consensus and controversy. J Am Coll Cardiol. 2011;58(1):1-10.

Schafer PE, Sacrinty MT, Cohen DJ, Kutcher MA, Gandhi SK, Santos RM, Little WC, Applegate RJ. Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice. Circ Cardiovasc Qual Outcomes. 2011;4(4):408-415.

Manogue MR, Sacrinty MT, Little WC, Gandhi SK, Kutcher MA, Santos RM, Turner SJ, Applegate RJ. Bleeding avoidance strategy: transition from femoral to radial artery as the preferred access for cardiac procedures. The Wake Forest academic medical center experience [abstract]. J Am Coll Cardiol. 2011;57(14 Suppl 1):E1057.

Schafer P, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Little WC, Applegate RJ. Cost effectiveness of drug-eluting stents versus bare metal stents in clinical practice: effect of stent length and diameter [abstract]. J Am Coll Cardiol. 2011;57(14 Suppl 1):E1184.

Turner S, Sacrinty MT, Little WC, Gandhi SK, Kutcher MA, Santos RM, Manogue MR, Applegate RJ. Cath lab utilization during transition to the radial artery as preferred access: the Wake Forest academic medical center experience [abstract]. J Am Coll Cardiol. 2011;57(14 Suppl):E1269.

Hermiller JB, Nikolsky E, Lansky AJ, Applegate RJ, Sanz M, Yaqub M, Sood P, Cao S, Sudhir K, Stone GW. Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention. 2011;7(3):307-313.

Applegate RJ. Long-term impact of periprocedural bleeding: when does it end? [editorial comment]. J Am Coll Cardiol. 2011;58(17):1757-1759.

Schafer PE, Sacrinty MT, Little WC, Gandhi SK, Kutcher MA, Santos RM, Cecile AC, Applegate RJ. Resource utilization for propensity matched radial and femoral catheterization and intervention [abstract]. J Am Coll Cardiol. 2011;58(20 Suppl B):B146-B147.

Stone GW, Sood P, Applegate RJ, Yaqub M, Hermiller JB, Newman W, Sanz M, Cao S, Bezenek S, Williams JE, Lansky A, Cutlip DE, Sudhir K. Comparison of everolimus-eluting and paclitaxel-eluting stents: first report of the five-year clinical outcomes from the SPIRIT III Trial [abstract]. J Am Coll Cardiol. 2011;58(20 Suppl B):B9.

Applegate RJ, Hermiller JB, Gordon PC, Yaqub M, Sood P, Su X, Cao S, Sudhir K, Stone GW. Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stents. EuroIntervention. 2011;7(9):1030-1042.

Gordon PC, Applegate RJ, Hermiller JB, Weinsier SB, Doostzadeh J, Cao S, Sudhir K, Lansky AJ, Stone GW. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry. Catheter Cardiovasc Interv. 2010;75(2):179-186.

Hayes KR, Applegate RJ, Sacrinty MT, Kutcher MA, Gandhi SK, Santos RM, Little WC. Target lesion revascularization after bare-metal or drug-eluting stents: clinical presentations and outcomes. J Invasive Cardiol. 2010;22(6):266-270.

Applegate RJ, Turi Z, Sachdev N, Ahmed A, Szyniszewski A, Foster M, Pratsos A, Shapiro T, Yakubov S, Shavelle D. The Angio-Seal Evolution registry: outcomes of a novel automated Angio-Seal vascular closure device. J Invasive Cardiol. 2010;22(9):420-426.

Applegate RJ. Unintended consequences of femoral artery closure devices [editorial comment]. J Invasive Cardiol. 2010;22(8):358-359.

Applegate RJ. Fractional flow reserve-guided stent therapy for multivessel disease: taking a closer look [editorial comment]. J Am Coll Cardiol. 2010;55(25):2822-2824.

Lambert ND, Applegate RJ. The comparative safety of bare-metal and drug-eluting intracoronary stents. Expert Rev Med Devices. 2010;7(5):611-624.

Holland BH, Applegate RJ. Femoral closure--devices and strategies in 2010. Interv Cardiol. 2010;5():93-95.

Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, Stone GW. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. EuroIntervention. 2010;6(4):437-446.

Applegate RJ, Stone GW. Rebuttal [letter]. Catheter Cardiovasc Interv. 2010;76(7):1078.

Applegate R, Hermiller J, Williams J, Gordon P, Doostzadeh J, Cao S, Su X, Sudhir K, Lansky A, Simonton C, et al. Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv. 2010;76(5):644-651.

Granger CB, Monk LM, Roettig ML, Al-Khalidi HR, Applegate RJ, Corbett CC, Garvey JL, Hathawy WR, Wilson BH, Jollis JG. State-wide care is improved in the Reperfusion of Acute MI in Carolina Emergency Department Emergency Response (RACE-ER) systems improvement program [abstract]. Circulation. 2010;122(21):2223-2224.

Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, et al. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System. J Am Coll Cardiol. 2010;56(25):2084-2089.

Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Little WC. Effect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomes. Circ Cardiovasc Interv. 2009;2():35-42.

Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Little WC. 3-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol Intv. 2009;2(3):231-239.

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System. Circulation. 2009;119(5):680-686.

Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Little WC. Three-year comparison of drug-eluting versus bare metal stents [abstract]. J Am Coll Cardiol. 2009;53(10 Suppl 1):A353.

Hayes KR, Applegate RJ, Sacrinty MT, Kutcher MA, Gandhi SK, Santos RM, Little WC. Clinical outcomes of bare metal stents versus drug-eluting stents target vessel revascularization: evidence for a high-risk bare metal stent cohort [abstract]. J Am Coll Cardiol. 2009;53(10 Suppl 1):A317-A318.

Lambert ND, Sacrinty MT, Ketch TR, Turner SJ, Santos RM, Daniel KR, Applegate RJ, Kutcher MA, Sane DC. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. Am Heart J. 2009;157(4):688-694.

Lambert ND, Sacrinty MT, Ketch TR, Turner SJ, Santos RM, Daniel KR, Applegate RJ, Kutcher MA, Sane DC. Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction [abstract]. J Am Coll Cardiol. 2009;53(10 Suppl 1):A319.

Santos RM, Sacrinty MJ, Kutcher MA, Gandhi SK, Little WC, Applegate RJ. Drug-eluting stent versus bare metal stent use in patients with chronic kidney disease [abstract]. J Am Coll Cardiol. 2009;53(10 Suppl 1):A393-A394.

Applegate R, Sacrinty M, Little W, Gandhi S, Kutcher M, Santos R. Prognostic implications of vascular complications following PCI. Catheter Cardiovasc Interv. 2009;74(1):64-73.

Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119(25):3198-3206.

Applegate RJ, Hermiller JB, Sanz M, Doostzadeh J, Pierson W, Su XL, Lansky AJ, Sudhir K, Stone GW. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomized trial [abstract]. Am J Cardiol. 2009;104(6A Suppl):150D.

Hermiller J, Applegate RJ, Sanz M III, Midei MG, Doostzadeh J, Pierson W, Sherry C, Sudhir K, Stone G. Evaluation of everolimus-eluting and paclitaxel-eluting stents in elderly patients: 2-year results from the SPIRIT III randomized trial [abstract]. Am J Cardiol. 2009;104(6A Suppl):142D-143D.

Lansky A, Applegate R, Hermiller JB, Cristea E, Dressler O, Sudhir K, Doostzadeh J, Su XL, Koo K, Stone G. Side-branch occlusion with XIENCE V everolimus-eluting and TAXUS EXPRESS2 paclitaxel-eluting stents: 2-year results from the SPIRIT III randomized trial [abstract]. Am J Cardiol. 2009;104(6A Suppl):135D.

Applegate RJ. Primary PCI for STEMI--pushing the limits [commentary]. J Invasive Cardiol. 2009;21(12):645-646.

Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Baki TT, Little WC. 'Off-label' stent therapy: 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2008;51(6):607-614.

Applegate RJ. Interventional management of femoral vascular complications: endovascular rescue for bleeding and ischemic complications [magazine article]. Cardiac Intervent Today. 2008;(Jan/Feb):31-34.

Applegate RJ, Graham SH, Gandhi SK, Kutcher MA, Sacrinty MT, Santos RM, Little WC. Culprit vessel PCI versus traditional cath and PCI for STEMI. J Invasive Cardiol. 2008;20(5):224-228.

Applegate RJ, Sacrinty MT, Kutcher MA, Gandhi SK, Santos RM, Little WC. Drug-eluting stents versus bare metal stents in saphenous vein grafts at 2 years [abstract]. J Am Coll Cardiol. 2008;51(10 Suppl B):B78.

Gandhi SK, Kay JD, Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Little WC. Drug-eluting stents for ST elevation myocardial infarction: evidence for benefit at two years [abstract]. J Am Coll Cardiol. 2008;51(10 Suppl B):B1.

Graham SH, Applegate RJ, Gandhi SK, Sacrinty MT, Baki TT, Santos RM, Little WC, Kutcher MA. Culprit vessel primary percutaneous coronary intervention for ST elevation myocardial infarction shorter door to balloon time [abstract]. J Am Coll Cardiol. 2008;51(10 Suppl B):B61.

Applegate RJ, Sacrinty MT, Kutcher MA, Kahl FR, Gandhi SK, Santos RM, Little WC. Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007. J Am Coll Cardiol Intv. 2008;1(3):317-326.

Applegate RJ, Sacrinty M, Kutcher M, Santos R, Gandhi S, Little W. Late outcomes of drug-eluting versus bare meta stents in saphenous vein grafts: propensity score analysis. Catheter Cardiovasc Interv. 2008;72(1):7-12.

Ketch TR, Turner SJ, Sacrinty MT, Lingle KC, Applegate RJ, Kutcher MA, Sane DC. Derived fibrinogen compared with C-reactive protein and brain natriuretic peptide for predicting events after myocardial infarction and coronary stenting. Am Heart J. 2008;156(2):234-240.

Applegate RJ, Sacrinty MT, Little WC, Santos RM, Gandhi SK, Kutcher MA. Incidence of coronary stent thrombosis based on academic research consortium definitions. Am J Cardiol. 2008;102(6):683-688.

Applegate RJ, Davis JM, Leonard JC. Treatment of ostial lesions using the Szabo technique: a case series. Catheter Cardiovasc Interv. 2008;72(6):823-828.

Applegate RJ, Sacrinty MT, Kutcher MA, Gandhi SK, Santos RM, Little WC. Prognostic implications of post percutaneous coronary intervention vascular complications [abstract]. Am J Cardiol. 2008;102(8A Suppl):9i.

Ketch TR, Turner SJ, Sacrinty MT, Lingle KC, Applegate RJ, Kutcher MA, Sane DC. ABO blood types: influence on infarct size, procedural characteristics and prognosis. Thromb Res. 2008;123(2):200-205.

Kirtane AJ, Gupta A, Iyengar S, Mehran R, Moses JW, Leon MB, Applegate R, Hannan E, Harjai K, Racz M, et al. Drug-eluting stent versus bare metal stent use: meta-analysis of randomized trials and observational studies [abstract]. Am J Cardiol. 2008;102(8A Suppl):31i.

Kirtane AJ, Gupta A, Iyengar S, Mehran R, Moses JW, Martin B, Applegate R, Hannan E, Harjai K, Racz M, et al. Drug-eluting stent versus bare metal stent use: meta-analysis of randomized trials and observational studies [abstract]. Circulation. 2008;118(18 Suppl 2):S1040.

Applegate RJ. Bivalirudin and DES: a PCI strategy that pays [commentary]. J Invasive Cardiol. 2007;19(2):69-70.

Applegate RJ, Sacrinty MT, Kutcher MA, Baki TT, Gandhi SK, Santos RM, Little WC. Comparison of drug-eluting versus bare metal stents on later frequency of acute myocardial infarction and death. Am J Cardiol. 2007;99(3):333-338.

Applegate RJ, Sacrinty MT, Kutcher MA, Baki TT, Gandhi SK, Santos RM, Kahl FR, Little WC. Propensity score analysis of vascular complications after diagnostic cardiac catheterization and percutaeous coronary intervention using thrombin hemostatic patch-facilitated manual compression. J Invasive Cardiol. 2007;19(4):164-170.

Applegate RJ, Sacrinty MT, Kutcher MA, Baki TT, Gandhi SK, Santos RM, Little WC. Vascular complications following cardiac catheterization and coronary intervention 1998-2005: influence of gender [abstract]. J Am Coll Cardiol. 2007;49(9 Suppl):193A.

McKee SA, Applegate RJ, Hoyle JR, Sacrinty MT, Kutcher MA, Sane DC. Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention. Am Heart J. 2007;154(1):159-164.

Aggarwal R, Ntim WO, Applegate RJ, Tumkosit M, Hundley WG, Hoyle JR. Contemporary cardiac imaging in hypertrophic obstructive cardiomyopathy. Cardiol Rev. 2007;24(8):17-20.

Applegate RJ, Sacrinty MT, Kutcher MA, Baki TT, Gandhi SK, Kahl FR, Santos RM, Little WC. Vascular complications in women after catheterization and percutaneous coronary intervention 1998-2005. J Invasive Cardiol. 2007;19(9):369-374.

Jollis JG, Roettig ML, Aluko AO, Anstrom KJ, Applegate RJ, Babb JD, Berger PB, Bohle DJ, Fletcher SM, Hoekstra JW, et al. Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA. 2007;298(20):2371-2380.

Ketch TR, Turner SJ, Sacrinty MT, Lingle KC, Applegate RJ, Kutcher MA, Sane DC. Derived fibrinogen versus brain natriuretic peptide and C-reactive protein as a predictor of events after myocardial infarction [abstract]. Circulation. 2007;116(16 Suppl II):II-578-579.

Noureddine ND, Schwartz DM, Garnett J, Applegate RJ. Takotsubo (stress-induced) cardiomyopathy in two women with suspected myocardial infarction. Hosp Physician. 2007;43(11):52-56.

Dauerman HL, Applegate RJ, Cohen DJ. Vascular closure devices: the second decade. J Am Coll Cardiol. 2007;50(17):1617-1626.

Applegate RJ, Sacrinty MT, Kutcher MA, Gandhi SK, Santos RM, Little WC. Vascular complications 1998-2007: evidence for better outcomes [abstract]. Am J Cardiol. 2007;100(8 Suppl 1):6L.

Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Baki TT, Gandhi SK, Little WC. Off-label DES vs. BMS treatment: outcomes at 2 years [abstract]. Am J Cardiol. 2007;100(8 Suppl 1):159L.

Call J, Sacrinty M, Applegate R, Little W, Santos R, Baki T, Gandhi S, Kahl F, Kutcher M. Automated contrast injection in contemporary practice during cardiac catheterization and PCI: effects on contrast-induced nephropathy. J Invasive Cardiol. 2006;18(10):469-474.

Applegate RJ, Upadhya B, Little WC, Xenakis M, Gandhi SK, Baki TT, Kahl FR, Kutcher MA. Late outcomes after intervention of vein grafts in diabetics with abciximab use. Int J Cardiol. 2006;111(1):136-141.

Daniel KR, Kutcher MA, Applegate RJ, Herrington DM. Clinical and angiographic risk factors for mechanical obstruction and no reflow following percutaneous coronary intervention [abstract]. Circulation. 2006;114(18 Suppl):II-731-732.

McKee SA, Applegate RJ, Hoyle JR, Sacrinty MT, Kutcher MA, Sane DC. Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention [abstract]. Circulation. 2006;114(18 Suppl):II-644.

Applegate RJ, Kutcher MA, Little WC, Sacrinty MT, Gandhi SK, Baki TT, Santos RM. Vascular complications after cath and percutaneous coronary intervention: thrombin hemostatic patch versus manual compression [abstract]. Circulation. 2006;114(18 Suppl):II-392.

Applegate RJ, Grabarczyk MA, Sane DC, Sacrinty MT, Goodin JE, Statonk GS, Baki TT, Gandhi SK, Kutcher MA, Little WC. PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients. J Invasive Cardiol. 2006;18(12):604-613.

Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006;48(12):2440-2447.

Applegate RJ, Kutcher MA, Little WC, Sacrinty MT, Gandhi SK, Baki TT, Santos RM. Drug-eluting stent treatment of patients with myocardial infarction--efficacy and safety at nine months [abstract]. Am J Cardiol. 2006;98(8A Suppl):75M.

Leonard JC, Sacrinty MT, Applegate RJ, Little WC, Baki TT, Gandhi SK, Santos RM, Kutcher MA. Timing of intervention in non-ST-segment elevation myocardial infarctions: nine month outcomes [abstract]. Am J Cardiol. 2006;98(8A Suppl):80M-81M.